 CAMBRIDGE, Mass., Jan. 06, 2022 GLOBE NEWSWIRE -- Codiak BioSciences, Inc. Nasdaq: CDAK, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13. 